US2005281779A1PendingUtilityA1

Enhancing immune responses to genetic immunization by using a chemokine

48
Assignee: CHIRON CORPPriority: Apr 22, 1998Filed: Mar 29, 2005Published: Dec 22, 2005
Est. expiryApr 22, 2018(expired)· nominal 20-yr term from priority
Inventors:Xavier Paliard
C12N 2770/24234A61K 2039/545C12N 2740/16234A61K 2039/53A61K 38/195A61K 39/29A61K 2039/55522A61K 39/12A61K 39/21
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The immune response to a DNA immunogen in a mammal can be enhanced by administration of a chemokine or a polynucleotide encoding the chemokine. This method can be used, for example, to immunize or vaccinate a mammal against an infectious disease or a tumor.

Claims

exact text as granted — not AI-modified
1 . An immunogenic composition, comprising: 
 a DNA immunogen; and    a chemokine or a polynucleotide encoding a chemokine.    
   
   
       2 . The immunogenic composition of  claim 1  wherein the DNA immunogen comprises a polynucleotide encoding a viral immunogen.  
   
   
       3 . The immunogenic composition of  claim 2  wherein the polynucleotide encodes a hepatitis C virus non-structural polypeptide.  
   
   
       4 . The immunogenic composition of  claim 3  wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.  
   
   
       5 . The immunogenic composition of  claim 2  wherein the polynucleotide encodes an HIV polypeptide.  
   
   
       6 . The immunogenic composition of  claim 5  wherein the HIV polypeptide is a gag polypeptide.  
   
   
       7 . The immunogenic composition of  claim 1  wherein the DNA immunogen comprises a polynucleotide encoding an immunogen expressed by a tumor.  
   
   
       8 . The immunogenic composition of  claim 1  wherein the chemokine is macrophage inflammatory protein 1α (MIP-1α).  
   
   
       9 . The immunogenic composition of  claim 1  wherein the chemokine is B lymphocyte chemokine (BLC).  
   
   
       10 . The immunogenic composition of  claim 1  further comprising a pharmaceutically acceptable carrier.  
   
   
       11 . A method of enhancing an immune response to a DNA immunogen in a mammal, comprising the step of: 
 administering to the mammal (i) a chemokine or a first polynucleotide encoding a chemokine and (ii) a DNA immunogen, whereby an immune response to the DNA immunogen is enhanced.    
   
   
       12 . The method of  claim 11  wherein a chemokine is administered.  
   
   
       13 . The method of  claim 12  wherein the chemokine and the DNA immunogen are co-administered.  
   
   
       14 . The method of  claim 12  wherein the chemokine is administered prior to administration of the DNA immunogen.  
   
   
       15 . The method of  claim 12  wherein the DNA immunogen is administered prior to administration of the chemokine.  
   
   
       16 . The method of  claim 11  wherein a first polynucleotide encoding the chemokine is administered.  
   
   
       17 . The method of  claim 16  wherein the first polynucleotide and the DNA immunogen are co-administered.  
   
   
       18 . The method of  claim 16  wherein the polynucleotide is administered prior to administration of the DNA immunogen.  
   
   
       19 . The method of  claim 16  wherein the DNA immunogen is administered prior to administration of the first polynucleotide.  
   
   
       20 . The method of  claim 16  wherein a second polynucleotide which comprises (a) the first polynucleotide and (b) the DNA immunogen is administered.  
   
   
       21 . The method of  claim 11  wherein the chemokine is macrophage inflammatory protein 1α (MIP-1α).  
   
   
       22 . The method of  claim 11  wherein the chemokine is B lymphocyte chemokine (BLC).  
   
   
       23 . The method of  claim 11  wherein the DNA immunogen comprises a polynucleotide which encodes a hepatitis C virus non-structural polypeptide.  
   
   
       24 . The method of  claim 23  wherein the hepatitis C virus non-structural polypeptide is selected from the group consisting of NS3, NS4, NS5a, and NS5b.  
   
   
       25 . The method of  claim 23  wherein the polynucleotide encodes an HIV polypeptide.  
   
   
       26 . The method of  claim 25  wherein the HIV polypeptide is a gag polypeptide.  
   
   
       27 . The method of  claim 11  wherein the mammal is a human.  
   
   
       28 . The method of  claim 11  wherein the immune response is an antibody response.  
   
   
       29 . The method of  claim 11  wherein the immune response is a cytotoxic T lymphocyte response.

Join the waitlist — get patent alerts

Track US2005281779A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.